{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:06:47Z","timestamp":1793898407806,"version":"4.8.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.rpth.2024.102600","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:03:14Z","timestamp":1729684994000},"page":"102600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood in\u00a0vitro"],"prefix":"10.1016","volume":"8","author":[{"given":"Matthew","family":"Bunce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Huang Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Chintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102600_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11239-016-1417-5","article-title":"Evaluation of anticoagulation selection for acute venous thromboembolism","volume":"43","author":"Badreldin","year":"2017","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2024.102600_bib2","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National trends in ambulatory oral anticoagulant use","volume":"128","author":"Barnes","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2024.102600_bib3","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/jth.13139","article-title":"Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102600_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102600_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chest.2017.02.009","article-title":"Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study","volume":"152","author":"Xu","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2024.102600_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11239-019-01954-2","article-title":"Direct oral anticoagulants: a review on the current role and scope of reversal agents","volume":"49","author":"Chaudhary","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2024.102600_bib7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMe1610510","article-title":"Engineering reversal\u2014finding an antidote for direct oral anticoagulants","volume":"375","author":"Hunt","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102600_bib8","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102600_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.rpth.2024.102600_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102600_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0950-3536(96)80068-0","article-title":"Factor XI deficiency","volume":"9","author":"Bolton-Maggs","year":"1996","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.rpth.2024.102600_bib12","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2024.102600_bib13","first-page":"S141","article-title":"Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors","volume":"87","author":"Kaatz","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102600_bib14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood-2013-09-529784","article-title":"How I treat target-specific oral anticoagulant-associated bleeding","volume":"123","author":"Siegal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102600_bib15","first-page":"189","article-title":"Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?","volume":"111","author":"Dickneite","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102600_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12245-018-0215-6","article-title":"The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review","volume":"11","author":"Hoffman","year":"2018","journal-title":"Int J Emerg Med"},{"key":"10.1016\/j.rpth.2024.102600_bib17","doi-asserted-by":"crossref","first-page":"P756","DOI":"10.1111\/jth.12149","article-title":"Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"11","author":"Baglin","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102600_bib18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1365-2516.2009.02043.x","article-title":"Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors","volume":"15","author":"Kenet","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102600_bib19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2516.2008.01663.x","article-title":"Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency","volume":"14","author":"O\u2019Connell","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102600_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1160\/TH09-03-0172","article-title":"Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies","volume":"102","author":"Livnat","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102600_bib21","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1055\/s-0039-1696685","article-title":"Single low dose of rFVIIa combined with antifibrinolytic agent is a simple and safe treatment for factor XI-deficient patients undergoing surgery","volume":"119","author":"Salomon","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102600_bib22","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"Levi","year":"2010","journal-title":"N\u00a0Engl J Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T19:34:41Z","timestamp":1738784081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924002954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2475037924002954"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102600","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood in\u00a0vitro","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102600"}}